Sally C M Lau, Malcolm Ryan, Jessica Weiss, Aline Fusco Fares, Miguel Garcia, Sabine Schmid, Shelley Kuang, Deirdre Kelly, Ming Sound Tsao, Penelope A Bradbury, Byoung Chun J Cho, Alexander Sun, Srinivas Raman, Andrew Hope, Meredith Giuliani, Benjamin H Lok, Andrea Bezjak, Geoffrey Liu, Natasha B Leighl, Frances A Shepherd, Adrian G Sacher
INTRODUCTION: The addition of durvalumab after chemoradiation therapy (CRT) in unresectable stage III NSCLC significantly improves survival. The benefit of this approach in elderly patients is controversial given the toxicity associated with CRT and, thus, may be underutilized. We sought to investigate the outcomes of elderly patients treated with CRT without or without durvalumab at our center. METHODS: We reviewed all stage III patients with NSCLC treated with CRT between 2018 and 2020...
December 2021: JTO clinical and research reports